ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden 11/08/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 08, 2025. This episode summarizes 5 key cardiology studies on topics like n-3 polyunsaturated fatty acids and left ventricular mass. Key takeaway: Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden.
Article Links:
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. (The New England journal of medicine)
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups. (Heart (British Cardiac Society))
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. (Journal of the American Heart Association)
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. (Journal of the American Heart Association)
Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/
Featured Articles
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41201837
Summary: This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41203298
Summary: This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195776
Summary: The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195775
Summary: This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.
Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195772
Summary: This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients.
Transcript
Today’s date is November 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.
Article number two. Sex differences in out-of-hospital cardiac arrest across age groups. This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.
Article number three. Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.
Article number four. Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.
Article number five. Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients.
Thank you for listening. Don’t forget to subscribe.
Keywords
n-3 polyunsaturated fatty acids, left ventricular mass, C.C.T.A., myocardial mass, pediatric cardiac arrest, age groups, C.A.D., eicosapentaenoic acid, large coronary thrombus burden, sex differences, out-of-hospital cardiac arrest, positron emission tomography, cardiovascular disease, survival to hospital discharge, coronary computed tomography angiography, P.E.T., myocardial ischemia, rivaroxaban, hemodialysis, vessel-specific myocardial mass, S.T.E.M.I., Voronoi method, coronary artery disease, O.H.C.A., S.T.-segment-elevation myocardial infarction, fish-oil supplementation, prognostic value, dual antiplatelet therapy, artificial intelligence, thrombus burden.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden 11/08/25 first appeared on Cardiology Today.
Article Links:
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. (The New England journal of medicine)
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups. (Heart (British Cardiac Society))
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. (Journal of the American Heart Association)
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. (Journal of the American Heart Association)
Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/
Featured Articles
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41201837
Summary: This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41203298
Summary: This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195776
Summary: The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195775
Summary: This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.
Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195772
Summary: This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients.
Transcript
Today’s date is November 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.
Article number two. Sex differences in out-of-hospital cardiac arrest across age groups. This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.
Article number three. Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.
Article number four. Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.
Article number five. Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients.
Thank you for listening. Don’t forget to subscribe.
Keywords
n-3 polyunsaturated fatty acids, left ventricular mass, C.C.T.A., myocardial mass, pediatric cardiac arrest, age groups, C.A.D., eicosapentaenoic acid, large coronary thrombus burden, sex differences, out-of-hospital cardiac arrest, positron emission tomography, cardiovascular disease, survival to hospital discharge, coronary computed tomography angiography, P.E.T., myocardial ischemia, rivaroxaban, hemodialysis, vessel-specific myocardial mass, S.T.E.M.I., Voronoi method, coronary artery disease, O.H.C.A., S.T.-segment-elevation myocardial infarction, fish-oil supplementation, prognostic value, dual antiplatelet therapy, artificial intelligence, thrombus burden.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden 11/08/25 first appeared on Cardiology Today.
In God we trust